Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by referring specialists.
Continuing the conversation, Juan Granada hears about Guido Ascione’s recent presentation on the global burden of degenerative mitral valve disease at NY Valves 2025.
View educational cardiology content from CRF Connect’s curated learning tracks.
This program provides an in-depth look at atrial shunts as a treatment option for HFpEF within the context of current medical therapies. Discussions of relevant measures of successful treatment, including hemodynamic measures and clinical outcomes. Finally, a comparison of devices under investigation will be provided.
This program will address the rapidly evolving field of shunt therapy as a treatment for heart failure. Specific populations of heart failure where this therapy may be most applicable will be discussed, along with the specific shunt types currently being tested. Results from studies already reported will be reviewed, combined with a look at the short and longer-term horizons for this therapeutic category.
This CME-accredited program will focus on advancements in the management of severe aortic stenosis (AS). Current guidelines recommend symptom-based treatment; however, emerging data suggests earlier intervention could improve patient outcomes. Expert faculty will discuss evolving perspectives on AS therapy, including modern metrics, the risks of delayed intervention, and potential changes to guidelines.